Allocating Approximately 25%–30% of Sales to R&D
First written in FY2017. 19 of 26 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2020: 1 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「R&D expenses for the interim consolidated accounting period totaled ¥3,027 million, representing 16.9% of net sales excluding royalties.」
While there were no material changes to the policy of allocating R&D expenses at a target ratio of 25% of net sales, the actual ratio for the interim consolidated accounting period was 16.9%. - FY2025-H1RestatedAnnual report
「R&D expenses for the interim consolidated accounting period totaled ¥3,243 million, representing 18.4% of net sales excluding royalties.」
There were no material changes to the policy of allocating R&D expenses at a target ratio of 25% of net sales. The actual ratio for the interim consolidated accounting period was 18.4% excluding royalties. - FY2024Full-year R&D expense ratio: 21.1%Annual report
「R&D expenses for the fiscal year totaled ¥7,484 million, representing 21.1% of net sales excluding royalties.」
While maintaining the policy of targeting an R&D expense ratio of 25% of net sales, the actual ratio for the fiscal year ended March 2024 was 21.1%. - FY2024-Q3RestatedAnnual report
「R&D expenses for the nine-month consolidated cumulative period totaled ¥5,098 million, representing 19.1% of net sales excluding royalties.」
There were no material changes to the policy of allocating R&D expenses at a target ratio of 25% of net sales, and the ratio for the nine-month cumulative period was 19.1% excluding royalties. - FY2024-Q2RestatedAnnual report
「R&D expenses for the six-month consolidated cumulative period totaled ¥3,410 million, representing 19.6% of net sales excluding royalties.」
While there were no material changes to the policy of targeting R&D expenses at 25% of net sales, the ratio for the cumulative quarter was 19.6% excluding royalties. - FY2023-Q3SoftenedAnnual report
「④ R&D expenses: target of 25% of net sales excluding royalties」
The wording changed from the previous range of approximately 25%–30% of net sales to a target of 25% of net sales excluding royalties, with the upper limit no longer specified. - FY2023-Q2RestatedAnnual report
「R&D expenses for the six-month consolidated cumulative period totaled ¥3,407 million, representing 19.7% of net sales excluding royalties.」
There were no material changes to the basic policy of allocating approximately 25%–30% of net sales to R&D expenses. The ratio for the six-month cumulative period was 19.7% excluding royalties. - FY2023-Q1RestatedAnnual report
「R&D expenses for the three-month consolidated cumulative period totaled ¥1,687 million, representing 20.3% of net sales excluding royalties.」
There were no material changes to the basic policy of allocating approximately 25%–30% of net sales to R&D expenses. The ratio for the quarter was 20.3% excluding royalties. - FY2022AdvancedAnnual report
「R&D expenses for the fiscal year totaled ¥9,005 million, up 24.9% year on year, and accounted for 25.8% of net sales.」
R&D expenses represented 25.8% of net sales, within the range under the basic policy of allocating approximately 25%–30% of net sales to R&D expenses. - FY2022-Q3AdvancedAnnual report
「R&D expenses for the nine-month consolidated cumulative period totaled ¥5,855 million, representing 20.8% of net sales, or 23.8% excluding royalties.」
The ratio of R&D expenses to net sales was 20.8% including royalties and 23.8% excluding royalties, up from 18.5% and 22.4%, respectively, in the previous cumulative quarter. The basic policy of allocating approximately 25%–30% of net sales to R&D expenses remains unchanged. - FY2022-Q2RestatedAnnual report
「R&D expenses for the six-month consolidated cumulative period totaled ¥3,802 million, representing 18.5% of net sales, or 22.4% excluding royalties.」
The company stated that there were no material changes to its R&D allocation policy and reported a ratio of 18.5% for the six-month cumulative period, or 22.4% excluding royalties. - FY2022-Q1RestatedAnnual report
「R&D expenses for the three-month consolidated cumulative period totaled ¥1,936 million, representing 16.4% of net sales, or 23.5% excluding royalties.」
There were no material changes to the basic policy of allocating approximately 25%–30% of net sales to R&D expenses. The ratio for the first quarter was 16.4% including royalties and 23.5% excluding royalties. - FY2021RestatedAnnual report
「R&D expenses for the fiscal year totaled ¥7,209 million, up 4.8% year on year, and accounted for 26.1% of net sales.」
There were no material changes to the policy of allocating approximately 25%–30% of net sales to R&D expenses, and the full-year ratio was 26.1%. - FY2021-Q2AdvancedAnnual report
「R&D expenses for the six-month consolidated cumulative period totaled ¥3,535 million, representing 26.1% of net sales.」
The ratio of R&D expenses to net sales was 26.1%, within the range under the basic policy of allocating approximately 25%–30% of net sales to R&D expenses. - FY2021-Q1RestatedAnnual report
「R&D expenses for the three-month consolidated cumulative period totaled ¥1,615 million, representing 23.2% of net sales.」
While there were no material changes to the policy of allocating approximately 25%–30% of net sales to R&D expenses, the actual ratio for the quarter was 23.2%. - FY2020RestatedAnnual report
「R&D expenses for the fiscal year totaled ¥6,877 million, representing 24.0% of net sales.」
There were no material changes to the basic policy of allocating approximately 25%–30% of net sales to R&D expenses, and the actual ratio for the fiscal year was 24.0%. - FY2020-Q3RestatedAnnual report
「③ R&D expenses: 25%–30% of net sales」
The company continues to apply the basic policy of allocating approximately 25%–30% of net sales to R&D expenses. The actual ratio for the nine-month consolidated cumulative period was 19.2%. - FY2020-Q2RestatedAnnual report
「③ R&D expenses: 25%–30% of net sales」
The company continues to apply the basic policy in its medium-term management plan of maintaining R&D expenses at 25%–30% of net sales. The actual ratio for the six-month consolidated cumulative period was 19.3%. - FY2020-Q1RestatedAnnual report
「R&D expenses for the three-month consolidated cumulative period totaled ¥1,288 million, representing 16.8% of net sales.」
While there were no changes to the basic policy of allocating approximately 25%–30% of net sales to R&D expenses, the actual ratio for the quarter was 16.8%. - FY2019AdvancedAnnual report
「R&D expenses for the fiscal year totaled ¥7,148 million, representing 25.2% of net sales.」
Under the basic policy of allocating approximately 25%–30% of net sales to R&D expenses, the actual ratio for the fiscal year was 25.2%, reaching the lower end of the target range. - FY2019-Q3RestatedAnnual report
「R&D expenses for the nine-month consolidated cumulative period totaled ¥4,992 million, representing 23.1% of net sales. There were no material changes in R&D activities.」
The company stated that there were no material changes to the basic policy of allocating approximately 25%–30% of net sales to R&D expenses, and reported an actual ratio of 23.1% for the cumulative quarter. - FY2019-Q2RestatedAnnual report
「R&D expenses for the six-month consolidated cumulative period totaled ¥3,287 million, representing 23.1% of net sales. There were no material changes in R&D activities.」
While there were no material changes to the basic policy of allocating approximately 25%–30% of net sales to R&D expenses, the ratio for the cumulative quarter was 23.1%. - FY2019-Q1RestatedAnnual report
「R&D expenses for the three-month consolidated cumulative period totaled ¥1,563 million, representing 21.6% of net sales.」
While there were no material changes to the basic policy of allocating approximately 25%–30% of net sales to R&D expenses, the ratio for the quarter was 21.6%. - FY2018-Q3RestatedAnnual report
「R&D expenses for the nine-month consolidated cumulative period totaled ¥5,150 million, representing 22.0% of net sales. There were no material changes in R&D activities.」
While noting that there were no material changes to the target management indicators, including the basic policy on R&D spending, the report states that R&D expenses represented 22.0% of net sales for the cumulative quarter. - FY2018-Q1RestatedAnnual report
「There were no material changes to the management metrics targeted by our group during the cumulative first-quarter period.」
The disclosure states that there were no material changes to the target management metrics, including R&D expenses. - FY2017First statedAnnual report
「Our basic policy is to allocate approximately 25% to 30% of sales to R&D expenses in order to develop innovative new drugs and achieve sustained growth. At the same time, we will allocate resources appropriately and in a balanced manner to pursue efficient R&D.」
The policy of allocating approximately 25% to 30% of sales to R&D expenses was disclosed for the first time as a target management metric. R&D expenses for the period were 26.5% of sales.